Rhythm Pharmaceuticals Inc.
(NASDAQ:RYTM) shares are trading higher on Wednesday.
On Tuesday, the company said the UK is expanding its marketing authorization for Imcivree (setmelanotide).
Read Also: Why Is Rhythm Pharma Stock Jumping Today?
RYTM Stock Rises On Expanded IMCIVREE Marketing Authorization On Tuesday, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) expanded the marketing authorization for Imcivree to include the treatment of obesity and control of hunger in adults and children 4 years of age and older with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment.
